EIB
European Investment Bank (EIB) provides lending, borrowing, and treasury services primarily in the European Union. The company offers project loans for the public and private sectors; loans to banks and other intermediaries; structured finance products; guarantees and securitization instruments for senior and subordinated debts; project bonds; equity and fund investment products such as infrastructure equity and debt funds, and environmental funds; and venture capital funds and security packages for funds. The company also offers microfinance; risk sharing finance for research, development, and innovation projects; finance and technical expertise for sustainable energy projects; infrastructure project advisory services; support for urban development projects; guarantees for transport infrastructure; and funding for public-private partnerships and small- and medium-sized enterprises. EIB serves the transportation, global loans, energy, industry, health, education, water, sewerage, infrastructure, services, telecommunications, agriculture, and fisheries sectors. European Investment Bank was founded in 1958 and is based in Luxembourg.
DPG Media operates as a media company. The Company provides wide range of news such as entertainment, sports, politics, market, and other related stories, as well as offers advertising services. DPG Media serves customers in Belgium.
Xeltis AG is a clinical-stage medical device company based in Zurich, Switzerland, with additional research and development facilities in Eindhoven, the Netherlands. Founded in 2006, Xeltis focuses on developing bio-absorbable heart valves and blood vessels that facilitate the body's natural healing processes. Its innovative technology, known as RestoreX, employs a therapeutic approach called Endogenous Tissue Restoration (ETR), which allows patients' own bodies to generate new heart valves. Through ETR, the porous structure of Xeltis' heart valves, made from bioabsorbable polymers, enables tissue to integrate with the implant, gradually forming a fully functional valve while the device itself is absorbed by the body. This groundbreaking approach aims to transform the treatment of heart valve disease by restoring natural heart valve function.
EclecticIQ B.V. is a global provider of threat intelligence, hunting, and response technology, supporting government organizations and commercial enterprises in enhancing their cybersecurity posture. Founded in 2014 and headquartered in Amsterdam, with additional offices in Herndon, Virginia; London, United Kingdom; and Chi?inau, Moldova, the company offers a range of products and services. These include the EclecticIQ Platform, a comprehensive threat intelligence platform; the EclecticIQ Fusion Center, which delivers multi-source threat intelligence bundles; and the EclecticIQ Academy for cyber threat intelligence training. The company also provides consulting services, team collaboration tools, and various integrations to optimize incident response and security controls. With a focus on building defenses against emerging threats, EclecticIQ has expanded its capabilities through acquisitions, such as Polylogyx's endpoint technology, to further enhance its offerings for clients facing sophisticated cyber threats.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
ISA Pharmaceuticals B.V. is a clinical-stage immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent virus infections. The Company has built a proprietary immunotherapy platform based on its Synthetic Long Peptide (SLP®) concept and its AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defense mechanisms towards fighting the disease, either alone or in combination with existing therapies.
The Medical Credit Fund is a non-profit health investment fund. It supports private healthcare facilities in Africa obtaining capital to strengthen and upgrade their operations in order to enhance access to affordable quality healthcare.
October SA is a lending platform designed for small and medium-sized enterprises (SMEs), facilitating direct borrowing from individual and institutional lenders. Established in France in 2014 under the name Lendix, the company rebranded to October SA in 2018. It operates as a pan-European platform with locations in France, Spain, Italy, and the Netherlands. By simplifying access to funding, October aims to empower businesses and enhance their growth potential. The platform emerged in response to regulatory changes that allowed increased competition in the lending sector, effectively democratizing financial resources for SMEs across Europe.
Ultimaker B.V., founded in 2011 and headquartered in Utrecht, the Netherlands, is a prominent developer of 3D printers and associated software tools. The company's product range includes models like the Ultimaker 3, Ultimaker 2+, and Ultimaker S5, catering to various applications such as prototyping, manufacturing, research, and education. Ultimaker is recognized for its open-source approach, fostering collaboration with its community to enhance innovation in the Maker industry. In addition to hardware, the company offers software solutions like Ultimaker Cura and Ultimaker Connect, which assist users in preparing 3D models for printing and managing their printers. With additional offices in the USA and Singapore, Ultimaker aims to facilitate a transition towards local and digital manufacturing, making 3D printing accessible and effective for professional designers and engineers.
Enevo Oy, founded in 2010 and headquartered in Espoo, Finland, specializes in waste management analytics. The company develops software that utilizes ultrasonic sonar technology to monitor fill levels in waste containers, providing valuable data to commercial clients, haulers, and municipalities. Enevo's solutions help streamline waste management operations and enhance the financial, environmental, and social impacts of waste handling. The company serves a diverse customer base, including restaurants, retailers, and commercial properties across North America and Europe, often through resellers in countries like the Netherlands, Belgium, and Norway. With a focus on innovation, Enevo offers a predictive, end-to-end solution that automates the planning and logistics of waste and recycling services. The company has secured over $34 million in private equity funding to support its technological advancements and operational processes.
Qredits is a financial institution that supports both aspiring and established entrepreneurs in successfully launching and managing their businesses. It specializes in providing microfinancing solutions, including commercial loans and microcredit, with amounts reaching up to €250,000. In addition to financial assistance, Qredits offers personal coaching and a range of entrepreneurial tools aimed at fostering business growth and innovation. The organization emphasizes a forward-looking approach, focusing on the potential of good ideas and the strength of entrepreneurship to turn dreams into reality. Through its mentoring and educational programs, Qredits aims to empower micro-entrepreneurs and stimulate the growth of small and medium-sized enterprises in the Netherlands.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.